John Ervin, MD
Ophthalmology · Macon, GANPI 1730153099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Alcon at 28.5% of the total.
Across 111 payments — averaging $31.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$858
- Dompe US, Inc.$289
- Sun Pharmaceutical Industries Inc.$210
- Bausch & Lomb Americas Inc.$167
- Carl Zeiss Meditec USA, Inc.$128
- plus $884 from 15 others
Across 1 payment — averaging $19,005 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$19K
What the payments were for
- Food & beverage$3,47798%
- Education$241%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 24 | $1,010 |
| AbbVie(2 entities) | 41 | $858 |
| Dompe US, Inc. | 8 | $289 |
| Sun Pharmaceutical Industries Inc. | 6 | $210 |
| Bausch & Lomb Americas Inc. | 3 | $167 |
| Carl Zeiss Meditec USA, Inc. | 1 | $128 |
| Astellas Pharma US Inc | 1 | $125 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $116 |
| Kala Pharmaceuticals, Inc. | 1 | $115 |
| Aerie Pharmaceuticals, Inc. | 2 | $106 |
| Tarsus Pharmaceuticals, Inc. | 3 | $77 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $67 |
| Glaukos Corporation | 2 | $57 |
| Apellis Pharmaceuticals, Inc. | 1 | $48 |
| Rayner Intraocular Lenses Limited | 1 | $36 |
| Oyster Point Pharma, Inc. | 2 | $32 |
| Eyevance Pharmaceuticals LLC | 2 | $27 |
| Amgen | 1 | $24 |
| Thea Pharma Inc. | 1 | $21 |
| Rxsight Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,546 in reported general payments places this provider in the 65th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 383 | $188,191 |
| RestasisCyclosporine | 108 | $109,062 |
| CombiganBrimonidine Tartrate/Timolol | 216 | $60,609 |
| RhopressaNetarsudil Mesylate | 109 | $41,940 |
| Alphagan PBrimonidine Tartrate | 119 | $34,518 |
| RocklatanNetarsudil Mesylat/Latanoprost | 52 | $25,638 |
| Travoprost | 169 | $21,943 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 105 | $20,368 |
| VyzultaLatanoprostene Bunod | 38 | $16,767 |
| Brimonidine Tartrate | 212 | $16,645 |
| Prednisolone Acetate | 302 | $14,153 |
| Lotemax SmLoteprednol Etabonate | 22 | $5,495 |
| Loteprednol Etabonate | 34 | $5,484 |
| Brinzolamide | 25 | $5,192 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 345 | $4,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $858 | $392,380826 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $106 | $67,577161 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $167 | $16,76738 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate, Prolensa | $116 | $15,17368 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Macon
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Jack ChapmanGainesville$244K
- Gregory LeeCumming$214K
- Puneet PandaMarietta$185K
- Jeffrey TranSuwanee$150K
- Evan SchoenbergAtlanta$130K
- Niraj DesaiCumming$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.